SynCardia Systems has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The expected price range given in the filing was $10 to $12 for 2.5 million shares, with an overallotment option for an additional 375,000 shares. At the maximum price, the total offering is valued up to $34.5 million. According to the S-1, the company intends to list on the Nasdaq Global Market under the symbol TAHT. (Source: 24/7 Wall St.)Continue reading→

In recognition of its contribution to new innovations and tools in the field of molecular diagnostics for the advancement of precision medicine, HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has been named a 2015 AZBio Fast Lane Company by the Arizona Bioindustry Association (AZBio).Continue reading→

By measuring DNA methylation, TGen researchers might determine which patients are at higher risk for relapse or metastasesContinue reading→

Continue reading→

Dr. Glen Weiss presents ‘Lung Microbiome’ study of those with and without lung cancer at the 16^th World Conference on Lung Cancer Continue reading→

TGen, Phoenix Children’s Hospital and Barrow Neurological Institute lead study of traumatic brain injuries following stroke Continue reading→

Company Presents Blinded Trial Data at WCLC 2015 Demonstrating that Its Non-Invasive Test Detects Early Lung CancerContinue reading→

DaVita Rx, a full-service specialty pharmacy for patients with complex conditions, today announced plans to open a new facility in Chandler, Arizona, by early 2016. The new Arizona facility allows DaVita Rx, the nation’s largest kidney care pharmacy, to further expand its reach in helping patients across the country gain access to specialty drugs and adhere to therapies.Continue reading→